AxoGen, Inc. (AXGN)
Market Cap | 338.74M |
Revenue (ttm) | 159.01M |
Net Income (ttm) | -21.72M |
Shares Out | 43.21M |
EPS (ttm) | -0.51 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 161,454 |
Open | 7.74 |
Previous Close | 7.77 |
Day's Range | 7.74 - 8.12 |
52-Week Range | 3.45 - 10.83 |
Beta | 1.07 |
Analysts | Strong Buy |
Price Target | 13.83 (+71.38%) |
Earnings Date | Mar 5, 2024 |
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc... [Read more]
Financial Performance
In 2023, AxoGen's revenue was $159.01 million, an increase of 14.74% compared to the previous year's $138.58 million. Losses were -$21.72 million, -24.98% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price forecast is $13.83, which is an increase of 71.38% from the latest price.
News
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12.
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...
Axogen Announces Promotions on Research and Development Team
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen...
Axogen Announces Transition of Finance Team Leadership
Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of Growth Nir Naor Appointed CFO to Replace Peter Mariani as Company Ali...
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...
Axogen, Inc. Reports 2023 Third Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™
ALACHUA, Fla. and TAMPA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...
Axogen to Participate at Upcoming Investor Conferences
ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
ALACHUA, Fla. and TAMPA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen, Inc. Reports 2023 Second Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen to Participate at Canaccord Genuity's 43rd Annual Growth Conference
ALACHUA and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...
Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen to Participate at Jefferies Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. Reports 2023 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...
Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., March 14, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...
Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...
Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...